Rhizome AI
United States· Est.
AI‑driven generative platform that accelerates drug discovery for cancer and immune diseases.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
AI‑driven generative platform that accelerates drug discovery for cancer and immune diseases.
OncologyImmunology
Technology Platform
Diffusion‑based generative AI combined with a biomedical knowledge graph and physics‑guided molecular simulations to design synthesizable drug candidates.
Opportunities
Rapid expansion into rare‑disease pipelines and deeper pharma partnerships could unlock sizable revenue streams.
Risk Factors
Reliance on external validation and the challenge of translating AI‑generated hits into clinically viable drugs pose execution risks.
Competitive Landscape
Competes with AI‑driven discovery firms like Insilico Medicine and Exscientia; differentiation stems from its diffusion generative core and integrated disease knowledge graph.